Viewing Protocol Section

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04924075
Ignite Creation Date: 2024-05-06 @ 4:15 PM
Last Modification Date: 2025-12-17 @ 12:57 AM
Study NCT ID: NCT04924075
Protocol Section: NCT04924075
Start Identification Module Data
Expand Identification Module Data
Brief Title: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Official Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
Acronym: None
Organization: Merck Sharp & Dohme LLC
Organization Class: INDUSTRY
Organization Study ID: 6482-015
Secondary IDs
Secondary ID Type Domain Link
MK-6482-015 OTHER None None
PT2977 OTHER None None
jRCT2011220024 REGISTRY None None
2023-504853-11-00 REGISTRY None None
2020-005028-13 EUDRACT_NUMBER EU CT None
Start Status Module Data
Status Verified Date: 2025-11
Overall Status: None
Study First Submit Date: 2021-06-08
Study First Submit QC Date:
Last Update Submit Date: 2025-11-20
Status: RECRUITING
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Merck Sharp Dohme LLC
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Merck Sharp Dohme LLC
Start Oversight Module Data 376335
Description Module: 379835
Study Last Update Post Date Type(Status Module):
Attachment: Upload